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Background: In recent years, anatomic pathology laboratories have been struck by new revenue policies
secondary to the Affordable Care Act. In particular, modifications to compensation for processing pros-
tatic core needle biopsies (PCNBs) have led to important reimbursement cuts. Herein, we explore a
hypothetical reduction in the costs for the processing of PCNBs using three simple, hypothetical methods
while maintaining high-standard patient care.
Materials and methods: We determined the number of blocks and slides used per case on all PCNBs
performed at our institution from August 2013 to September 2014 and calculated the total procedural
cost for each case and for the total number of cases processed during the study period based on a
published estimated procedural cost. We then estimated the procedural cost of three different proposed
hypothetical scenarios that consisted in reducing the number of blocks used per case. A Student t test
was used to assess the difference between real and hypothetical costs.
Results: A total of 4,406 paraffin blocks were used to process 363 PCNBs with a total annual procedural
cost of $26,303. By implementing any of the hypothetical scenarios, the annual procedural cost was
significantly reduced; the reduction could potentially be as low as $8,978 (P < 0.0001).
Conclusions: This study illustrates three hypothetical alternatives that could dramatically reduce the
procedural costs of PCNBs while maintaining high-quality care. Implementation of these scenarios at a
global scale could potentially have an impact on health-care cost in the USA of several millions of dollars
per year.
© 2019 APPS& KPS, Published by Elsevier Korea LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostatic carcinoma (PCa) is the most commonly diagnosed
cancer in males in the United States of America, accounting for one
in four newly diagnosed cancers each year. In 2015, this number
equated to approximately 220,800 new cases and 27,540 deaths.1
Currently, the 10e12 prostate core needle biopsy (PCNB) sam-
pling protocol is considered the standard of care for the diagnosis of
PCa due to its higher cancer detection and lower false negative
rates.2 It also provides precise information for localized therapy and
improves the correlation with Gleason grading.3e5
Several major changes have taken place since the Patient Pro-
tection and Affordable Care Act was signed into law on March 23,
2010. The Act directed the Centers for Medicare Services to revise
high-volume medical services, including PCNBs, to adjustSchool of Medicine, 1400 NW
).
ed by Elsevier Korea LLC. This is areimbursement fees. The most notorious example was a 52%
reimbursement cut in the technical component of the 88305 Cur-
rent Procedural Terminology (CPT) code, with a mild increase of 2%
in the professional component. However, the total payment for
88305 suffered an overall reduction of 33%.6 This represents a drop
from $69.78 to approximately $33.70 per case coded as 88305. The
consequences of these new policies could represent a loss of as high
as $460 million in revenue per year for some laboratories.6e8
Hence, we propose three hypothetical scenarios that could
potentially help overcome these reimbursement cuts by imple-
menting simple, rapid protocols, aimed to decrease procedural
costs while maintaining high-standard patient care.2. Materials and methods
2.1. Acquisition of data
Under an institutional review board, we retrieved and reviewed
the pathology reports of all the PCNBs performed at our institutionn open access article under the CC BY-NC-ND license (http://creativecommons.org/
Prostate International 7 (2019) 15e1816over a one-year period from August 2013 to September 2014. We
generated a database including the demographic information, the
histopathological diagnosis, the number of paraffin blocks and
slides used per case, the site of the prostate samples, and the
location and the grading of the carcinoma cases for further analysis.
2.2. Cost analysis
Our current active protocol for processing PCNBs is in accor-
dance with the current consensus recommendations from the As-
sociation of Directors of Anatomic and Surgical Pathology, the
College of American Pathologists and the International Society of
Urological Pathology.9 It recommends using one PCNB per
container and per paraffin block. In addition, our institutional
protocol includes the cut of deeper levels from each paraffin block
and a total of two slides prepared per block; thus, a 12-PCNB case
usually consists of 12 paraffin blocks and 24 slides. Based on pub-
lished estimates by Buesa,10 we calculated the procedural cost per
case from grossing to slide preparation in a manual/automated
laboratory and included the estimated cost to cut and stain addi-
tional sections of the same paraffin block to account for the deeper
sections taken from each block. The results were used to estimate
the total procedural cost per case for the one-year study period
using the actual numbers of supplies and cases at our institution,
and numbers were obtained based on the three different hypo-
thetical scenarios (see below).
2.3. Statistical analysis
Results are reported in absolute and relative frequencies with
means and standard deviation or medians and ranges, accordingly.
The difference in the cost of the actual scenario at our institution




The pathology reports of 363 PCNBs belonging to 355 men
(median age: 65, interval: 43e90 years) were reviewed and
included in the study. A total of 149 (41%) cases were diagnosed
with PCa. The 10e12 core needle biopsy protocol was performed in
167 (46%) cases. Most of the sites sampled yielded benign prostatic
tissue (80%), followed by Gleason 6 adenocarcinoma/Grade Group 1
(5.5%), Gleason 7/Grade Groups 2 and 3 (4.4%), Gleason 8/Grade
Group 4 (1.4%), Gleason 9/Grade Group 5 (1.1%), and Gleason 10/
Grade Group 5 (0.3%). High-grade prostatic intraepithelial
neoplasm was observed in 28 (0.7%) of the sampled sites, and 68
(1.6%) sites were deemed equivocal for malignancy. The tissue ob-
tained from three sites (<1%) was too small to be interpreted. TheTable 1
Distribution of positive cases according to Gleason score and anatomical location.
Score LLB LLM LLA LB LM LA
PIN-HG 3 1 3 3 1 4
Gleason 6 27 22 22 12 21 21
Gleason 7 19 14 16 13 15 16
Gleason 8 6 4 6 6 2 3
Gleason 9 3 5 3 3 4 4
Gleason 10 1 1 2 1 1 1
Total 59 47 52 38 44 49
Left (289)
LA, left apex; LB, left base; LM, left middle; LLA, left lateral apex; LLB, left lateral base, LLM
apex; RB, right base; RM, right middle; RLA, right lateral apex; RLB, right lateral base; Rmost frequent biopsy site was the left lateral base (98.9%, n ¼ 359/
363) followed by the left lateral mid (97.8%, n¼ 355/363); however,
PCawasmore frequently diagnosed on the right side of the prostate
without reaching a statistical significance (P ¼ 0.94). Table 1 sum-
marizes the distribution of the 149 positive cases according to
Gleason score and anatomical location. Cancer involvement was
evenly distributed throughout the 12 anatomic locations included
in the 10e12 biopsy protocol. PCa was primarily diagnosed in in-
dividuals aged between 60 and 80 years, whereas those <50 years
were more rarely affected.3.2. Cost analysis of the study period
Based on the gross description in the pathology reports and our
current protocol, we calculated the total number of blocks used per
case (n ¼ 4,406) and the total number of slides required for each
case (n ¼ 8,812) that were used during the study period. The me-
dian number of blocks and slides used per case was 12 (2e24) and
24 (4e48), respectively. We then used a published estimate10 of
$4.71 dollars for each case to calculate the procedural cost per case,
as well as the total expenditure over the study period, from
grossing to slide preparation in amanual/automated laboratory and
a cost of $1.26 for cutting additional deeper sections.10 The total
procedural cost for the one-year study period totaled $26,303.82.
The average procedural cost per case was approximately $72.46
(±15.25). Extra costs derived from additional deeper cuts or
immunohistochemistry were not included in the calculation.
We then explored the following three possibilities to try to
reduce the procedural costs in the histopathological laboratories: 1)
embedding two PCNBs per paraffin block, 2) embedding three
PCNBs per paraffin block following a “sequential” approach, and 3)
embedding three PCNBs per paraffin following a “schematic”
approach. In addition, we calculated the cost of including all six
PCNBs from the right side and all PCNBs from the left in two
separate cassettes. Although this practice is strongly discouraged,
some institutions continue to process PCNBs using this unfavorable
methodology.9,11,12 Table 2 summarizes the amount of consumables
(slides and paraffin blocks) and the hypothetical procedural cost
per case over the entire study period in all different scenarios
compared with the actual expenses.3.3. Two PCNBs per paraffin block
According to this hypothetical scenario, each paraffin block
would contain two PCNBs, one of which would be inked. By
implementing this scheme, the number of blocks would be reduced
to 2,225, and approximately 4,450 slides would be generated. In
contrast to the actual cost, the total procedural cost would be
reduced to $13,283.25, and the average procedural cost per case
would be reduced to $36.6 (±7.5). This would represent nearly aRA RM RB RLA RLM RLB Total
2 1 3 4 3 0 28
22 17 19 13 21 22 239
15 21 14 19 15 17 194
5 5 5 6 6 7 61
7 5 3 2 4 6 49
0 0 1 2 1 1 12
51 49 45 46 50 53 583
Right (294)
, left lateral middle; PIN-HG, prostatic intraepithelial neoplasia-high grade; RA, right
LM, right lateral middle.
Table 2
Consumables, average, and total procedural costs per case and for the study period of the real and hypothetical scenarios.
Supplies/Cost 1 PCNB real 2 PCNB n 3 PCNB schematic 3 PCNB sequential 6 PCNB P
Per block
Blocks (n) 4,406 2,225 1,759 1,469 1,033 <0.001
Slides (n) 8,812 4,450 3,518 3,008 2,066 <0.001
Average cost per case ($, ±) 72.5 (15.2) 36.6 (7.5) 29 (9) 24.7 (5.4) 17 (8.9) <0.001
Total cost ($) 26,303.82 13,283.25 10,501.23 8,978.88 6,167 <0.001
PCNB, prostatic core needle biopsy.
R. Ruiz-Cordero et al. / Cost-containment protocols for prostate core needle biopsies 1750% reduction compared with our currently practiced protocol for
PCNBs (P < 0.001).3.4. Three PCNBs per paraffin blockdsequential model
This hypothetical scenario is similar to the previous one but
involves submitting three PCNBs per cassette in the order of their
submission, even if a specific biopsy site is not sampled. Two PCNBs
would be inked in two different colors, and the biopsy in themiddleFig. 1. Schematic model for submitting three PCNBs per paraffin block. This figure il-
lustrates the 12 anatomic locations commonly sampled in prostatic biopsies. Each
biopsy has a specific location and is inked and submitted in a paraffin block based on
this scheme. If any of the biopsy sites is not sampled, then that spot(s) is not used;
therefore, all cases with 4 to 12 biopsies will be placed in four paraffin blocks.
LLA, left lateral apex; LLB, left lateral base, LLM, left lateral middle; PCNB, prostatic core
needle biopsy; RLA, right lateral apex; RLB, right lateral base; RLM, right lateral middle.would not be inked, to avoid mixing of colors13 (e.g., left lateral
base, left lateral middle, left lateral apex in one cassette with blue,
no ink, and red ink, respectively). With this protocol, cases con-
taining one to three biopsies will have one paraffin block and two
slides, cases with four to six biopsies will have two paraffin blocks
and four slides, and so forth. Therefore, most of the cases following
the 10e12 biopsy protocol would be processed in three to four
paraffin blocks and six to eight slides. Each additional PCNB can be
inked accordingly and sequentially submitted; for example, a 24-
PCNB case could potentially be submitted in eight paraffin blocks
and 16 slides. The total procedural cost by using this method would
be reduced to $8,979.88, and the average procedural cost per case
would be reduced to $24.73 (±5.4). This scenario yields the
maximum amount of savings (up to 65%). However, it could
generate some confusion at the time of grossing and during sign-
out.3.5. Three PCNBs per paraffin blockdschematic model (preferred)
Of the 363 cases, we focused only on 232 (35%) cases that
encompassed between 4 and 12 PCNBs per case. We believe that
cases with less than four PCNBs can be processed by embedding
one PCNB per cassette, without affecting the overall cost. For cases
with more than 12 PCNBs, any additional biopsy can be embedded
separately in one block. By restricting the use of this model to cases
with 4 to 12 PCNBs, three biopsies can be submitted in each block,
and every alternate biopsy can be inked as previously described
(Fig. 1). The difference relies in the fact that if a specific site were
not sampled, then the corresponding spot would be left empty on
the block and on the slide. This schematic model will be easy to
follow by pathologist assistants and will help to reduce mistakes at
the time of grossing and sign-out. Based on specific colors and their
corresponding location, pathologist should be easily able to orient
each sample at the time of sign-out because regardless of the
number of PCNBs submitted, each biopsy will have a specific
location. The estimated total procedural cost of this model was
calculated to be $10,501.23 with an average procedural cost
per case of $29 (±9). We prefer this method because it can poten-
tially avoid confusion and facilitate convenient grossing and
interpretation.4. Discussion
During the past few years, legislation on the quality of health-
care, cost containment, patient safety, and satisfaction has steadily
increased, indirectly impacting overall health-care costs. Currently,
there is no consensus on the number of PCNBs that can be safely
placed in a container or a paraffin block for adequate pathological
analysis.9,11 Available data suggest that processing multiple PCNBs
in a single container or paraffin block compromises pathological
evaluation.9,11,12 It has been reported that there is a potential risk of
losing as much as 40% of tissue when submitting more than two
PCNBs per paraffin block.11,12,14 However, other authors have found
Prostate International 7 (2019) 15e1818that the yield of cancer is similar with the submission of one to
three PCNBs per cassette.11,15 Moreover, when using the appro-
priate type of cassettes, one could potentially include asmany as six
PCNBs per cassette.16 The limiting factor in bundling multiple
PCNBs for histologic processing appears to be the impending
entanglement of the biopsies16 and the technical processing of the
samples. Nevertheless, because this is an operator-dependent
process, a dedicated experienced histotechnologist could poten-
tially resolve this issue.13,16 At our institution, for example, we have
a dedicated histotechnologist who processes kidney core needle
biopsies at two microns and is able to include more than two cores
in the same paraffin block with optimal results. In addition to
allocating experienced personnel to the process, placing PCNBs
between two nylon meshes before fixation to avoid tissue entan-
gling and fragmentation has shown to decrease entanglement and
increase the frequency of cancer diagnosis.17
By implementing the new Patient Protection and Affordable
Care Act fee schedule, the reimbursement for the technical
component for the CPT code 88305 used for PCNBs almost halved.
In addition, the number of containers used also has an important
impact on revenue. Firoozi et al18 recently published one alterna-
tive to reduce the number of containers using a similar model of
inking and submitting three PCNBs per container at the time of
biopsy before sending the samples to the histology laboratory.
Although we did not include this approach in our cost analysis, the
addition of this step before the samples are delivered to the his-
tology lab, coupled with any of the methods described in this study,
could have the largest impact on reducing costs.
The limitations of the present study include the hypothetical
nature of the scenarios; actual implementation should be under-
taken to determine the real costs and additional hurdles and ben-
efits that have not been studied or foreseen. The costs were based
on a published estimate that did not include adjustments for
inflation throughout the years; hence, pricing might vary slightly.
Additional costs, such as the processing time, storage space,
grossing time, other supplies, and pathologists' time to review
slides, should be taken into consideration at the time of imple-
mentation.We did not directly analyze the impact of decreasing the
time that each pathologist would take to review a case. However,
we believe that it would be substantial. The steady increase in the
number of PCNBs performed each year will also have a tremendous
impact not only in costs but also in the transportation, reviewing,
and archiving of paraffin blocks and slides; hence, a cost-effective
solution is highly desirable.
In summary, reimbursement cuts are here to stay, and quality of
healthcare, cost containment, and patient safety and satisfaction
will play an even more important role in the years to come. At-
tempts focused on cost containment to overcome reimbursement
cuts have been proposed2. In the present study, we analyzed the
potential impact on decreasing procedural costs that could be
achieved by modifying the grossing of PCNBs. Any of the proposedalternatives could potentially help to reduce a portion of health-
care costs in the United States of America, in the range of hundreds
of thousands to several millions of dollars per year.
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